Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection.
Streptococcus pneumoniae is the leading pathogen of community-acquired pneumonia and is a main cause of infectious deaths. However, little is known about host-pathogen interaction in human lung tissue. We tested the hypothesis that human alveolar macrophages (AMs) and alveolar epithelial cells (AECs) are important for initiating the host response against S. pneumoniae, and we evaluated the role of Toll-like receptor (TLR) 2, TLR4, and p38 mitogen-activated protein kinase (MAPK) signaling in the inflammatory response after pneumococcal infection. We established a novel model of acute S. pneumoniae infection using vital human lung specimens. In situ hybridization analysis showed that S. pneumoniae DNA was detected in 80 to 90% of AMs and 15 to 30% of AECs after in vitro infection accompanied by increased expression of inflammatory cytokines. Enhanced phosphorylation of p38 MAPK and increased TLR2 and 4 mRNA expression were observed in infected lung tissue. Thirty to fifty percent of AMs and 10 to 20% of AECs showed evidence of apoptosis 24 hours after pneumococcal infection. After macrophage deactivation with Clodronate/liposomes, infected lung tissue exhibited a significantly decreased release of inflammatory mediators. Inhibition of p38 MAPK signaling markedly reduced inflammatory cytokine release from human lungs, whereas TLR2 blockade revealed only minor effects. AMs are central resident immune cells during S. pneumoniae infection and are the main source of early proinflammatory cytokine release. p38 MAPK holds a major role in pathogen-induced pulmonary cytokine release and is a potential molecular target to modulate overwhelming lung inflammation.
Xu
Feng
F
Medical Clinic III, Campus Lübeck, University of Schleswig-Holstein, Lübeck, Germany.
Droemann
Daniel
D
Rupp
Jan
J
Shen
Huahao
H
Wu
Xiaohong
X
Goldmann
Torsten
T
Hippenstiel
Stefan
S
Zabel
Peter
P
Dalhoff
Klaus
K
D000208:Acute Disease; D017209:Apoptosis; D039481:CD11b Antigen / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D004269:DNA, Bacterial / Q000235:genetics; D004789:Enzyme Activation; D005786:Gene Expression Regulation; D006801:Humans; D017403:In Situ Hybridization; D007249:Inflammation / Q000378:metabolism; D008168:Lung / Q000276:immunology / Q000382:microbiology* / Q000473:pathology*; D016676:Macrophages, Alveolar / Q000378:metabolism; D008954:Models, Biological; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000382:microbiology* / Q000473:pathology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D051195:Toll-Like Receptor 2 / Q000235:genetics; D051197:Toll-Like Receptor 4 / Q000235:genetics; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D039481:CD11b Antigen; D004269:DNA, Bacterial; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D048051:p38 Mitogen-Activated Protein Kinases; D053148:Caspase 3